Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate® ) and BAY 81-8973 (Kovaltry® ) in patients with severe or moderate haemophilia A in prophylaxis.

Megías-Vericat JE, Bonanad S, Haya S, Cid AR, Marqués MR, Monte-Boquet E, Pérez-Alenda S, Bosch P, Querol F, Poveda JL.

Haemophilia. 2019 Mar 13. doi: 10.1111/hae.13733. [Epub ahead of print] No abstract available.

PMID:
30866068
2.

Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A.

Megías-Vericat JE, Bonanad S, Haya S, Cid AR, Marqués MR, Monte E, Pérez-Alenda S, Bosch P, Querol F, Poveda JL.

Thromb Res. 2019 Feb;174:151-162. doi: 10.1016/j.thromres.2018.12.027. Epub 2019 Jan 3.

PMID:
30634166
3.

Predictive factors of immune tolerance treatment response in severe haemophilia A patients with inhibitors: A real-world report from a single centre, mixed retrospective-prospective long-term study.

Haya S, Solano C, Cid AR, Argilés B, Hervás D, Querol F, Bonanad S, Casaña P.

Haemophilia. 2019 Mar;25(2):e97-e100. doi: 10.1111/hae.13660. Epub 2019 Jan 3. No abstract available.

PMID:
30604912
4.

Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery.

Peyvandi F, Mamaev A, Wang JD, Stasyshyn O, Timofeeva M, Curry N, Cid AR, Yee TT, Kavakli K, Castaman G, Sytkowski A.

J Thromb Haemost. 2019 Jan;17(1):52-62. doi: 10.1111/jth.14313. Epub 2018 Dec 20.

PMID:
30362288
5.

Unraveling the effect of silent, intronic and missense mutations on VWF splicing: contribution of next generation sequencing in the study of mRNA.

Borràs N, Orriols G, Batlle J, Pérez-Rodríguez A, Fidalgo T, Martinho P, López-Fernández MF, Rodríguez-Trillo Á, Lourés E, Parra R, Altisent C, Cid AR, Bonanad S, Cabrera N, Moret A, Mingot-Castellano ME, Navarro N, Pérez-Montes R, Marcellin S, Moreto A, Herrero S, Soto I, Fernández-Mosteirín N, Jiménez-Yuste V, Alonso N, de Andrés-Jacob A, Fontanes E, Campos R, Paloma MJ, Bermejo N, Berrueco R, Mateo J, Arribalzaga K, Marco P, Palomo Á, Quismondo NC, Iñigo B, Nieto MDM, Vidal R, Martínez MP, Aguinaco R, Tenorio JM, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Dobón M, Aguilar C, Vidal F, Corrales I.

Haematologica. 2019 Mar;104(3):587-598. doi: 10.3324/haematol.2018.203166. Epub 2018 Oct 25.

6.

Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project.

Pérez-Rodríguez A, Batlle J, Corrales I, Borràs N, Rodríguez-Trillo Á, Lourés E, Cid AR, Bonanad S, Cabrera N, Moret A, Parra R, Mingot-Castellano ME, Navarro N, Altisent C, Pérez-Montes R, Marcellini S, Moreto A, Herrero S, Soto I, Fernández Mosteirín N, Jiménez-Yuste V, Alonso N, de Andrés Jacob A, Fontanes E, Campos R, Paloma MJ, Bermejo N, Berrueco R, Mateo J, Arribalzaga K, Marco P, Palomo Á, Castro Quismondo N, Iñigo B, Nieto MDM, Vidal R, Martínez MP, Aguinaco R, Tenorio M, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Dobón M, Aguilar C, Batlle F, Vidal F, López-Fernández MF.

PLoS One. 2018 Jun 20;13(6):e0197876. doi: 10.1371/journal.pone.0197876. eCollection 2018.

7.

α2-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC:α2M Levels Are Associated with Venous Thromboembolism.

Martos L, Ramón LA, Oto J, Fernández-Pardo Á, Bonanad S, Cid AR, Gruber A, Griffin JH, España F, Navarro S, Medina P.

Thromb Haemost. 2018 Apr;118(4):630-638. doi: 10.1055/s-0038-1629902. Epub 2018 Feb 15.

8.

Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors.

Mancuso ME, Fischer K, Santagostino E, Oldenburg J, Platokouki H, Königs C, Escuriola-Ettingshausen C, Rivard GE, Cid AR, Carcao M, Ljung R, Petrini P, Altisent C, Kenet G, Liesner R, Kurnik K, Auerswald G, Chambost H, Mäkipernaa A, Molinari AC, Williams M, van den Berg HM; European Pediatric Network for Haemophilia Management (PedNet) the REMAIN (REal life MAnagement of children with INhibitors) Study Group.

Thromb Haemost. 2017 Dec;117(12):2274-2282. doi: 10.1160/TH17-01-0059. Epub 2017 Dec 6.

PMID:
29212115
9.

Allogeneic hematopoietic cell transplantation in an adult patient with Glanzmann thrombasthenia.

Cid AR, Montesinos P, Sánchez-Guiu I, Haya S, Lorenzo JI, Sanz J, Moscardo F, Puig N, Planelles D, Bonanad S, Sanz GF, Vicente V, González-Manchón C, Lozano ML, Rivera J, Sanz MA.

Clin Case Rep. 2017 Oct 5;5(11):1887-1890. doi: 10.1002/ccr3.1206. eCollection 2017 Nov.

10.

Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients.

Borràs N, Batlle J, Pérez-Rodríguez A, López-Fernández MF, Rodríguez-Trillo Á, Lourés E, Cid AR, Bonanad S, Cabrera N, Moret A, Parra R, Mingot-Castellano ME, Balda I, Altisent C, Pérez-Montes R, Fisac RM, Iruín G, Herrero S, Soto I, de Rueda B, Jiménez-Yuste V, Alonso N, Vilariño D, Arija O, Campos R, Paloma MJ, Bermejo N, Berrueco R, Mateo J, Arribalzaga K, Marco P, Palomo Á, Sarmiento L, Iñigo B, Nieto MDM, Vidal R, Martínez MP, Aguinaco R, César JM, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Cornudella R, Aguilar C, Vidal F, Corrales I.

Haematologica. 2017 Dec;102(12):2005-2014. doi: 10.3324/haematol.2017.168765. Epub 2017 Sep 29.

11.

Bleeding risk of surgery and its prevention in patients with inherited platelet disorders.

Orsini S, Noris P, Bury L, Heller PG, Santoro C, Kadir RA, Butta NC, Falcinelli E, Cid AR, Fabris F, Fouassier M, Miyazaki K, Lozano ML, Zúñiga P, Flaujac C, Podda GM, Bermejo N, Favier R, Henskens Y, De Maistre E, De Candia E, Mumford AD, Ozdemir GN, Eker I, Nurden P, Bayart S, Lambert MP, Bussel J, Zieger B, Tosetto A, Melazzini F, Glembotsky AC, Pecci A, Cattaneo M, Schlegel N, Gresele P; European Hematology Association - Scientific Working Group (EHA-SWG) on thrombocytopenias and platelet function disorders.

Haematologica. 2017 Jul;102(7):1192-1203. doi: 10.3324/haematol.2016.160754. Epub 2017 Apr 6.

12.

A simplified assay for the quantification of circulating activated protein C.

Martos L, Bonanad S, Ramón LA, Cid AR, Bonet E, Corral J, Miralles M, España F, Navarro S, Medina P.

Clin Chim Acta. 2016 Aug 1;459:101-104. doi: 10.1016/j.cca.2016.05.025. Epub 2016 Jun 2.

PMID:
27262823
13.

Novel mutations in RASGRP2, which encodes CalDAG-GEFI, abrogate Rap1 activation, causing platelet dysfunction.

Lozano ML, Cook A, Bastida JM, Paul DS, Iruin G, Cid AR, Adan-Pedroso R, Ramón González-Porras J, Hernández-Rivas JM, Fletcher SJ, Johnson B, Morgan N, Ferrer-Marin F, Vicente V, Sondek J, Watson SP, Bergmeier W, Rivera J.

Blood. 2016 Sep 1;128(9):1282-9. doi: 10.1182/blood-2015-11-683102. Epub 2016 May 27.

14.

Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.

Parra Lopez R, Nemes L, Jimenez-Yuste V, Rusen L, Cid AR, Charnigo RJ, Baumann JA, Smith L, Korth-Bradley JM, Rendo P.

Thromb Haemost. 2015 Oct;114(4):676-84. doi: 10.1160/TH14-09-0760. Epub 2015 Aug 13.

PMID:
26293201
15.

Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm.

Batlle J, Pérez-Rodríguez A, Corrales I, López-Fernández MF, Rodríguez-Trillo Á, Lourés E, Cid AR, Bonanad S, Cabrera N, Moret A, Parra R, Mingot-Castellano ME, Balda I, Altisent C, Pérez-Montes R, Fisac RM, Iruín G, Herrero S, Soto I, de Rueda B, Jiménez-Yuste V, Alonso N, Vilariño D, Arija O, Campos R, Paloma MJ, Bermejo N, Toll T, Mateo J, Arribalzaga K, Marco P, Palomo Á, Sarmiento L, Iñigo B, Nieto Mdel M, Vidal R, Martínez MP, Aguinaco R, César JM, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Cornudella R, Aguilar C, Borràs N, Vidal F.

Thromb Haemost. 2016 Jan;115(1):40-50. doi: 10.1160/TH15-04-0282. Epub 2015 Aug 6.

PMID:
26245874
16.

Analysis of 65 pregnancies in 34 women with five different forms of inherited platelet function disorders.

Civaschi E, Klersy C, Melazzini F, Pujol-Moix N, Santoro C, Cattaneo M, Lavenu-Bombled C, Bury L, Minuz P, Nurden P, Cid AR, Cuker A, Latger-Cannard V, Favier R, Nichele I, Noris P; European Haematology Association - Scientific Working Group on Thrombocytopenias and Platelet Function Disorders.

Br J Haematol. 2015 Aug;170(4):559-63. doi: 10.1111/bjh.13458. Epub 2015 Apr 21.

PMID:
25899604
17.

Functional and molecular characterization of inherited platelet disorders in the Iberian Peninsula: results from a collaborative study.

Sánchez-Guiu I, Antón AI, Padilla J, Velasco F, Lucia JF, Lozano M, Cid AR, Sevivas T, Lopez-Fernandez MF, Vicente V, González-Manchón C, Rivera J, Lozano ML.

Orphanet J Rare Dis. 2014 Dec 24;9:213. doi: 10.1186/s13023-014-0213-6.

18.

Bleeding before prophylaxis in severe hemophilia: paradigm shift over two decades.

Nijdam A, Altisent C, Carcao MD, Cid AR, Claeyssens-Donadel S, Kurnik K, Ljung R, Nolan B, Petrini P, Platokouki H, Rafowicz A, Thomas AE, Fischer K; PedNet and CANAL study groups.

Haematologica. 2015 Mar;100(3):e84-6. doi: 10.3324/haematol.2014.115709. Epub 2014 Dec 19. No abstract available.

19.

Comparison of a new chemiluminescent immunoassay for von Willebrand factor activity with the ristocetin cofactor-induced platelet agglutination method.

Cabrera N, Moret A, Caunedo P, Cid AR, Vila V, España F, Aznar JA.

Haemophilia. 2013 Nov;19(6):920-5. doi: 10.1111/hae.12203. Epub 2013 Jun 4.

PMID:
23730809
20.

Factor VIII products and inhibitor development in severe hemophilia A.

Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeyssens-Donadel S, van Geet C, Kenet G, Mäkipernaa A, Molinari AC, Muntean W, Kobelt R, Rivard G, Santagostino E, Thomas A, van den Berg HM; PedNet and RODIN Study Group.

N Engl J Med. 2013 Jan 17;368(3):231-9. doi: 10.1056/NEJMoa1208024.

21.

Large deletion in the Factor VIII gene (F8) involving segmental duplications in int22h shows no haematological phenotype in female carriers, but may be embryonic lethal in males.

Casaña P, Mayo S, Monfort S, Orellana C, Haya S, Cid AR, Roselló M, Oltra S, Martínez F.

Br J Haematol. 2012 Jul;158(1):138-40. doi: 10.1111/j.1365-2141.2012.09092.x. Epub 2012 Mar 19. No abstract available.

PMID:
22429151
22.

Ultrasonography in the monitoring of management of haemarthrosis.

Aznar JA, Abad-Franch L, Perez-Alenda S, Haya S, Cid AR, Querol F.

Haemophilia. 2011 Sep;17(5):826-8. doi: 10.1111/j.1365-2516.2011.02538.x. Epub 2011 Apr 19. No abstract available.

PMID:
21501338
23.

First application of MLPA method in severe von Willebrand disease. Confirmation of a new large VWF gene deletion and identification of heterozygous carriers.

Cabrera N, Casaña P, Cid AR, Moret A, Moreno M, Palomo A, Aznar JA.

Br J Haematol. 2011 Jan;152(2):240-2. doi: 10.1111/j.1365-2141.2010.08400.x. Epub 2010 Oct 19. No abstract available.

PMID:
20955405
24.

Identification of deletion carriers in hemophilia B: quantitative real-time polymerase chain reaction or multiple ligation probe amplification.

Casaña P, Haya S, Cid AR, Oltra S, Martínez F, Cabrera N, Aznar JA.

Transl Res. 2009 Mar;153(3):114-7. doi: 10.1016/j.trsl.2008.12.006. Epub 2009 Jan 27.

PMID:
19218093
25.
26.

Novel missense mutation c.2685G>C (p.Q895H) in VWF gene associated with very low levels of VWF mRNA.

Cabrera N, Casaña P, Cid AR, Haya S, Moret A, Aznar JA.

Ann Hematol. 2009 Mar;88(3):245-7. doi: 10.1007/s00277-008-0576-7. Epub 2008 Aug 20.

PMID:
18712522
27.

One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype.

Cid AR, Calabuig M, Cortina V, Casaña P, Haya S, Moret A, Cabrera N, Aznar JA.

Haemophilia. 2008 Sep;14(5):1049-54. doi: 10.1111/j.1365-2516.2008.01781.x. Epub 2008 Jun 5.

PMID:
18540892
28.

Founder haplotype associated with the factor VIII Asp1241Glu polymorphism in a cohort of mild hemophilia A patients.

Casaña P, Martínez F, Cabrera N, Cid AR, Aznar JA.

J Thromb Haemost. 2008 Aug;6(8):1428-30. doi: 10.1111/j.1538-7836.2008.02983.x. Epub 2008 Apr 17. No abstract available.

29.

Severe and moderate hemophilia A: identification of 38 new genetic alterations.

Casaña P, Cabrera N, Cid AR, Haya S, Beneyto M, Espinós C, Cortina V, Dasí MA, Aznar JA.

Haematologica. 2008 Jul;93(7):1091-4. doi: 10.3324/haematol.12344. Epub 2008 Apr 9.

30.

Inhibitors in haemophilia A: current management and open issues.

Haya S, Moret A, Cid AR, Cortina V, Casaña P, Cabrera N, Aznar JA.

Haemophilia. 2007 Dec;13 Suppl 5:52-60. doi: 10.1111/j.1365-2516.2007.01574.x. Review.

PMID:
18078398
31.

Treatment in a haemophiliac A patient with paroxysmal atrial fibrillation and ischemic heart disease.

Cid AR, Zorio E, Haya S, Zúñiga P, Rueda J, Casaña P, Cabrera N, Arnau MA, Aznar JA.

Haemophilia. 2007 Nov;13(6):760-2. No abstract available.

PMID:
17973853
32.

Inhibitor development in one patient and laboratory discrepancies in several families with both mild haemophilia and Arg531Cys mutation.

Cid AR, Casaña P, Cabrera N, Haya S, Cortina V, Aznar JA.

Haemophilia. 2007 Mar;13(2):206-8.

PMID:
17286776
33.
34.
35.

Molecular analyses in hemophilia B families: identification of six new mutations in the factor IX gene.

Espinós C, Casaña P, Haya S, Cid AR, Aznar JA.

Haematologica. 2003 Feb;88(2):235-6. No abstract available.

36.

Haemophilia prophylactic treatment in Spain.

Tusell J, Cid AR, Sosa R, Villar A, Lucia JF.

Haemophilia. 2002 Sep;8(5):729-30. No abstract available.

PMID:
12199690
37.

A comparison of FVII:C and FVIIa assays for the monitoring of recombinant factor VIIa treatment.

Cid AR, Lorenzo JI, Haya S, Montoro JM, Casaña P, Aznar JA.

Haemophilia. 2001 Jan;7(1):39-41.

PMID:
11136379
38.

Influence of methylene blue photoinactivation treatment on coagulation factors from fresh frozen plasma, cryoprecipitates and cryosupernatants.

Aznar JA, Bonanad S, Montoro JM, Hurtado C, Cid AR, Soler MA, De Miguel A.

Vox Sang. 2000;79(3):156-60.

PMID:
11111234
39.

Clotting factors in cryoprecipitate and cryo-supernatant prepared from MB-treated fresh plasma.

Aznar JA, Montoro JM, Cid AR, Bonanad S, Hurtado C, Soler MA, De Miguel A.

Transfusion. 2000 Apr;40(4):493. No abstract available.

PMID:
10773066
40.

Response to plasma exchange and steroids as combined therapy for patients with thrombotic thrombocytopenic purpura.

de la Rubia J, López A, Arriaga F, Cid AR, Vicente AI, Marty ML, Sanz MA.

Acta Haematol. 1999;102(1):12-6.

PMID:
10473882

Supplemental Content

Support Center